These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 200952)

  • 21. Live cytomegalovirus vaccination of healthy volunteers: eight-year follow-up studies.
    Stern H
    Birth Defects Orig Artic Ser; 1984; 20(1):263-9. PubMed ID: 6329366
    [No Abstract]   [Full Text] [Related]  

  • 22. Vaccination against Herpes group viruses, in particular, cytomegalovirus.
    Plotkin SA
    Monogr Paediatr; 1979; 11():58-74. PubMed ID: 226876
    [No Abstract]   [Full Text] [Related]  

  • 23. Cytomegalovirus vaccine: persistence of humoral immunity following immunization of renal transplant candidates.
    Sachs GW; Simmons RL; Balfour HH
    Vaccine; 1984 Sep; 2(3):215-8. PubMed ID: 6099649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of cytomegalovirus disease in transplant recipients.
    Pidgeon GB; Bailey RR
    N Z Med J; 1993 Nov; 106(967):468-9. PubMed ID: 8233192
    [No Abstract]   [Full Text] [Related]  

  • 25. Cytomegalovirus infection.
    Alford CA
    Ala J Med Sci; 1985 Apr; 22(2):169-89. PubMed ID: 2988358
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.
    Adler SP; Starr SE; Plotkin SA; Hempfling SH; Buis J; Manning ML; Best AM
    J Infect Dis; 1995 Jan; 171(1):26-32. PubMed ID: 7798679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytomegalovirus vaccine: a realistic appraisal.
    Phillips CF
    Hosp Pract; 1979 Feb; 14(2):75-80. PubMed ID: 218880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.
    Wang Z; La Rosa C; Maas R; Ly H; Brewer J; Mekhoubad S; Daftarian P; Longmate J; Britt WJ; Diamond DJ
    J Virol; 2004 Apr; 78(8):3965-76. PubMed ID: 15047812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse effects of cytomegalovirus vaccination in mice.
    Jordan MC
    J Clin Invest; 1980 Apr; 65(4):798-803. PubMed ID: 6244333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Letter: Cytomegalovirus infection in utero.
    Plotkin SA
    Lancet; 1974 May; 1(7863):924. PubMed ID: 4133433
    [No Abstract]   [Full Text] [Related]  

  • 31. Cytomegalovirus-induced immune suppression. I. Humoral immunity.
    Howard RJ; Najarian JS
    Clin Exp Immunol; 1974 Sep; 18(1):109-18. PubMed ID: 4377712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Murine model for immunoprophylaxis of cytomegalovirus infection. I. Efficacy of immunization.
    Minamishima Y; Eizuru Y; Yoshida A; Fukunishi R
    Microbiol Immunol; 1978; 22(11):693-700. PubMed ID: 85239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The status of cytomegalovirus vaccine.
    Starr SE; Friedman HM; Plotkin SA
    Rev Infect Dis; 1991; 13 Suppl 11():S964-5. PubMed ID: 1664136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.
    John S; Yuzhakov O; Woods A; Deterling J; Hassett K; Shaw CA; Ciaramella G
    Vaccine; 2018 Mar; 36(12):1689-1699. PubMed ID: 29456015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination against cytomegalovirus.
    Plotkin SA
    Arch Virol Suppl; 2001; (17):121-34. PubMed ID: 11339541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus infection in the neonate and its prevention.
    Stern H
    Postgrad Med J; 1977 Oct; 53(624):588-91. PubMed ID: 201930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of cytomegalovirus disease. Report of a conference.
    Plotkin S
    Pediatr Infect Dis; 1984; 3(1):1-4. PubMed ID: 6322140
    [No Abstract]   [Full Text] [Related]  

  • 38. Cytomegalovirus vaccine work progressing.
    Gunby P
    JAMA; 1982 Sep; 248(12):1424-5. PubMed ID: 6287051
    [No Abstract]   [Full Text] [Related]  

  • 39. Perspectives for the control of cytomegalovirus infections in bone marrow transplant recipients.
    Pollard RB; Merigan TC
    Transplant Proc; 1978 Mar; 10(1):241-5. PubMed ID: 205021
    [No Abstract]   [Full Text] [Related]  

  • 40. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
    Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z
    J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.